COMMUNIQUÉS West-GlobeNewswire

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
09/03/2026
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or [...]
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
09/03/2026
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • [...]
SafeSpace Global Opens Nashville Office, Builds Operational Infrastructure to Support Revenue Growth
09/03/2026
Company Transitions from Remote Operations to Physical Facility; Plans Technology Demonstration Center, Expanded Workforce and Investor Events NASHVILLE, TN., March 09, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global [...]
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and [...]
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
09/03/2026
Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit LAGUNA HILLS, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. ( [...]
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
09/03/2026
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and [...]
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
09/03/2026
-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity [...]
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
09/03/2026
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth [...]
HNL Lab Medicine’s Career Connections Program Builds the Next Generation of Clinical Laboratory Professionals
09/03/2026
ALLENTOWN, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine is helping address the national shortage of clinical laboratory professionals through its Career Connections program, a hands-on initiative that [...]
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
09/03/2026
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3 β plus RAS inhibition [...]
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
09/03/2026
March 9, 2026 Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage [...]
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
09/03/2026
Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the [...]
First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics
09/03/2026
Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI 1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This [...]
CenTrak Showcases Next Generation of AI-Enhanced Location Intelligence Platform at HIMSS 2026
09/03/2026
New AI-powered insights and platform innovations expand how healthcare organizations use real-time location data to improve safety, streamline operations, and maximize RTLS value NEWTOWN, Pa., March 09, 2026 (GLOBE [...]
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK ), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially [...]
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
09/03/2026
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated [...]
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026
The Hydrafacial Treatment and SkinStylus Nano-Channeling Protocol Addresses Rising Consumer Demand for Combination Treatments That Can Improve Performance and Enhance Results LONG BEACH, Calif., March 09, 2026 (GLOBE [...]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company [...]

Pages